查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999396

大鼠和小鼠模型市場：按類型、模型類型、服務類型、應用和最終用戶分類－2026-2032年全球市場預測

Rat & Mouse Model Market by Species, Model Type, Service Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，大鼠和小鼠模型市場價值將達到 26.1 億美元，到 2026 年將成長到 27.8 億美元，到 2032 年將達到 47.4 億美元，複合年成長率為 8.89%。

主要市場統計數據
基準年 2025 26.1億美元
預計年份：2026年 27.8億美元
預測年份 2032 47.4億美元
複合年成長率 (%) 8.89%

現代小動物臨床前生態系統的框架，重點在於模型選擇、轉化有效性和操作決策壓力。

依賴大鼠和小鼠模型的臨床前研究生態系統正處於轉折點，科學進步、監管改善和商業化路徑的轉變在此交會。幾十年來，這些小型哺乳動物模型為闡明疾病機制提供了至關重要的機制，並彌合了實驗室研究與臨床實踐之間的鴻溝。然而，如今的研究對模型選擇、研究設計和可重複性提出了更嚴格的檢驗。研究人員和機構領導者越來越需要在轉化有效性和運作限制之間權衡利弊，努力適應物種、基因建構和服務模式的選擇會對研究進度和最終成果產生重大影響的環境。

基因編輯、表現型分析和外包等技術進步如何重塑臨床前研究中的模型選擇、研究設計和倫理實踐。

受技術成熟、科研重點轉變和倫理規範發展等因素的驅動，大鼠和小鼠模型研究領域發生了翻天覆地的變化。基因工程工具的普及使得建構高度特異性的模型成為可能，讓研究人員以前所未有的精確度研究疾病相關結構。這種技術能力正在重塑研究團隊進行假設檢驗的方式，使其從統一的模型轉向根據研究問題和機制終點量身定做的模型。同時，表現型分析和生物影像成像技術的進步也透過提供更豐富、多模態的測量數據，提高了臨床前訊號的可解讀性。

本研究評估了 2025 年實施的累積關稅措施如何促進供應鏈韌性、採購重新設計以及臨床前營運的地理遷移。

2025年實施的關稅政策調整及相關貿易措施，為支持臨床前研究的全球供應鏈帶來了新的成本動態和營運考量。採購團隊和設施管理人員在採購動物、特殊飼料、設備和進口試劑時，面臨更複雜的計算。鑑於育種項目、醫療用品和特殊耗材之間的相互依存關係，即使是小幅的關稅上調也會影響前置作業時間和庫存策略。因此，相關人員在採取更積極的供應商多元化策略，盡可能選擇在地採購，並擴大安全庫存規模，以減少中斷。

將動物物種、模型配置、研究目的、最終用戶、分銷管道、研究類型和服務模式與營運決策聯繫起來的詳細分段理解。

細分市場層面的洞察揭示了影響大鼠和小鼠模型領域實驗設計、供應商選擇和產品組合優先順序的許多細節考量。根據動物種類，市場被細分為小鼠和大鼠兩大類，這種基本的二分法會影響生理有效性、研究範圍和飼養需求。小鼠通常是基因工程的主要平台，而大鼠則更適用於需要更大血容量的研究或利用更高認知複雜性的行為分析。根據模型類型，市場可細分為疾病特異性、基因敲除模型、基因轉殖模型和異種移植模型。疾病特異性模型可再細分為心血管疾病模型、感染疾病模型、神經系統疾病模型和腫瘤模型。基因敲除模型、基因轉殖模型和疾病特異性模型之間的選擇取決於機制研究問題、所需的表現型保真度以及下游轉化研究的考量。

區域實際情況和監管細微差別決定了全球研究中心的模型採購、研究順序以及育種和表現型分析能力的策略分配。

區域趨勢對大鼠和小鼠模型領域的研究設計、資源取得和監管策略制定有顯著影響。美洲地區聚集了許多學術機構、生技Start-Ups和綜合製藥研發中心，因此對快速取得專業模型和高通量表現型分析的需求日益成長。這種環境促進了服務交付的創新，並促使人們更加重視速度和資料完整性。歐洲、中東和非洲的法規結構和基礎設施成熟度各不相同，既有成熟的研究中心，也有新興市場。在這些地區，監管協調以及區域性育種和表現型分析中心的建設對於推動多中心合作研究至關重要。同時，倫理標準和動物福利準則仍是營運規劃的重點。亞太地區在商業服務和學術研究方面都經歷了快速的產能擴張，對育種基礎設施和專業合約研究組織（CRO）能力的投入巨大。該地區的相關人員往往優先考慮成本效益、規模和進行大規模研究計畫的能力，同時加強對數據品質和動物福利方面國際標準的遵守。

競爭考察揭示了品質保證、廣泛的客製化選項、合作夥伴關係和卓越的客戶服務如何推動市場領導地位。

在鼠類模型生態系統中，主要企業普遍關注品質保證、客製化能力和整合資訊服務。尋求差異化的市場導向企業正投資於穩健的育種項目、遺傳檢驗流程和標準化的表現型分析流程，從而降低測試間差異並提高可重複性。通用，提供整合模型建置、育種管理、生物監測和綜合數據分析等模組化服務供應商，正在幫助申辦方縮短研發週期並降低轉換風險。

為了改善轉換結果，領導者需要採取切實可行的優先措施，加強模型選擇、供應商管治、早期檢驗、資料整合和福利實踐。

產業領導者應採取一系列切實可行的步驟，將洞見轉化為營運優勢，並提升大鼠和小鼠研究的轉化應用效果。首先，系統化建構模型選擇決策框架，將生物學假設與模型屬性、表現型分析要求和監管終點連結起來。此框架可減少主觀選擇偏差，並明確基因改造構建體、基因敲除方法和疾病特異性模型之間的權衡取捨。其次，在進行大規模療效研究之前，應投資早期表現型分析和試驗研究，以檢驗關鍵終點。這種循序漸進的方法可降低後續失敗的風險，並有助於更合理地分配資源。

採用透明的混合方法研究途徑，結合與關鍵相關人員的訪談、技術文獻綜述、供應商能力比較和供應鏈情境分析。

本文總結的見解是基於混合方法研究途徑，該策略結合了與關鍵相關人員的對話、嚴謹的文獻整合以及比較營運分析。主要研究包括對機構研究人員、採購人員和服務供應商營運經理進行結構化訪談，以確定實際存在的限制和優先事項。這些定性研究結果與技術文獻和監管指南進行了交叉比對，以確保其符合當前最佳實踐以及關於動物福利、採購流程透明度和試驗設計方面不斷變化的期望。

策略結論的整合突顯了精心選擇的模型、嚴格的檢驗、綜合資料策略和供應彈性如何提高轉化研究的成功率。

總之，大鼠和小鼠模型仍然是臨床前藥物發現和開發的重要工具，但其價值取決於模型選擇的謹慎、檢驗的嚴格以及操作規範的穩健。基因工程和表現型分析的進步拓寬了實驗的可能性，但也提高了品質保證和可重複性的要求。與關稅相關的供應鏈壓力進一步推動了積極主動的籌資策略和能力的地理分散。綜上所述，各組織需要將科學選擇與實際操作結合，並在採購、試驗設計和資料管理等所有領域加強管治。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 大鼠和小鼠模型市場：按類型分類

  • 大鼠模型
    • 非近交系大鼠模型
    • 近交系大鼠模型
    • 基因改造大鼠模型
    • 免疫力缺乏大鼠模型
  • 小鼠模型
    • 非近交系小鼠模型
    • 近交系小鼠模型
    • 基因改造小鼠模型
      • 擊倒小鼠模型
      • 基因轉殖小鼠模型
      • 人源化小鼠模型
    • 免疫力缺乏小鼠模型
      • 裸鼠模型
      • SCID小鼠模型
      • NOG/NSG小鼠模型

第9章：按模型類型分類的大鼠和小鼠模型市場

  • 近交系模型
  • 非近交系模型
  • 基因改造模型
    • 淘汰賽模特兒
      • 永久性敲除模型
      • 條件性敲除模型
      • 歸納敲除模型
    • 基因改造模型
    • 人形模型
    • 敲入式模型
  • 異質性移植模型
    • 細胞株衍生的異種移植模型
    • 患者來源的異種移植模型
  • 類似車型
  • 化學誘導模型
  • 餵食誘導模型
  • 手術誘導模型
  • 自發性疾病模型
  • 記者模型

第10章：大鼠與小鼠模型市場：依服務類型分類

  • 標準模式條款
    • 活體動物
    • 冷凍保存的胚胎和精子
  • 自訂模型創建
    • 基因編輯的設計與構建
    • 胚胎學和顯微注射服務
    • 驗證和品管
  • 繁殖和群體管理
    • 制定育種策略
    • 殖民地擴張與維護
    • 健康監測
  • 冷凍保存/解凍
    • 精子冷凍保存
    • 胚胎冷凍保存
    • 復甦服務
  • 血統重組和健康狀況改善
  • 表現型分析和行為測試
    • 生理表現型分析
    • 行為和認知測試
  • 生物檢測服務
    • 功效測試
    • 疾病誘發和監測
    • 外科建模
  • 諮詢和監管合規支持

第11章：大鼠與小鼠模型市場：依應用分類

  • 藥物發現與篩檢
    • 目標識別與檢驗
    • 高通量篩檢
    • 先導化合物的最佳化
  • 臨床前療效試驗
    • 劑量反應研究
    • 聯合治療研究
  • 藥物動力學和動態
    • 吸收、分佈、代謝和排泄
    • 暴露-反應模型
  • 安全性和毒性測試
    • 急性毒性
    • 慢性毒性
    • 致癌性
    • 生殖和發育毒性
  • 疾病機轉及病理學研究
  • 生物標記的發現與檢驗
  • 轉化仿生研究
  • 教育和培訓

第12章：大鼠與小鼠模型市場：依最終使用者分類

  • 製藥公司
    • 主要跨國製藥公司
    • 中型和專業製藥公司
  • 生技公司
    • 一家歷史悠久的生物技術公司
    • 新興虛擬生技公司
  • 受委託的研究機構
    • 世界 CRO
    • 小眾臨床前合約研究組織
  • 學術和研究機構
    • 大學
    • 獨立研究機構
  • 政府和公共部門的研究機構
  • 非營利組織和基金會
  • 產業聯盟和夥伴關係

第13章：大鼠和小鼠模型市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：大鼠與小鼠模型市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：大鼠和小鼠模型市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國大鼠與小鼠模型市場

第17章：中國鼠類模型市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Biocytogen Pharmaceuticals Co., Ltd.
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience International, Inc.
  • Cyagen Biosciences, Inc.
  • Envigo RMS, LLC
  • GemPharmatech Co., Ltd.
  • genOway SA
  • Harbour BioMed
  • Hera BioLabs, Inc.
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs SA
  • Oncodesign Precision Medicine
  • Oriental BioService Co., Ltd.
  • Ozgene Pty Ltd.
  • PerkinElmer, Inc.
  • Pharmatest Services Oy
  • PolyGene AG
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • TransCure bioServices
  • TransTech Pharma, Inc.
  • TransViragen, Inc.
  • Vivo Bio Tech Ltd.
Product Code: MRR-3A2E844FF329

The Rat & Mouse Model Market was valued at USD 2.61 billion in 2025 and is projected to grow to USD 2.78 billion in 2026, with a CAGR of 8.89%, reaching USD 4.74 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.61 billion
Estimated Year [2026] USD 2.78 billion
Forecast Year [2032] USD 4.74 billion
CAGR (%) 8.89%

Framing the contemporary small mammal preclinical ecosystem with emphasis on model choice, translational validity, and operational decision-making pressures

The preclinical research ecosystem that relies on rat and mouse models sits at an inflection point defined by converging scientific advances, regulatory refinement, and shifting commercialization pathways. Over decades these small mammal models have provided indispensable mechanistic insight and a translational bridge from bench to bedside, yet today's studies demand closer scrutiny of model selection, study design, and reproducibility. Researchers and organizational leaders increasingly weigh translational validity against operational constraints, and they navigate an environment where choices about species, genetic construct, and service modality materially influence timelines and scientific outcomes.

Contextualizing the current landscape requires appreciation for how genetic engineering breakthroughs, improvements in phenotyping technologies, and more rigorous ethical and welfare standards have reshaped the expectations placed on preclinical platforms. These changes amplify the need for integrated data strategies, cross-functional decision frameworks, and clearer go/no-go criteria early in development. As such, laboratory leaders and sponsors must reconcile the enduring value of mouse and rat models with the imperative to optimize predictive performance, reduce variability, and align studies with regulatory and payer expectations.

This introduction frames the subsequent analysis by emphasizing the practical trade-offs teams face: selecting the right model type for a biological question, ensuring methodological rigor, and managing the logistics of sourcing, housing, and data integration. The core objective of this executive summary is to convert these high-level dynamics into actionable insight for those making operational and strategic decisions in preclinical research.

How technological advances in genetic editing, phenotyping, and operational outsourcing are reshaping model selection, study design, and ethical practices in preclinical research

The landscape of rat and mouse model research has undergone transformative shifts driven by technological maturation, shifting scientific priorities, and evolving ethical expectations. Genetic engineering tools have democratized the creation of highly specific model types, allowing researchers to pursue disease-relevant constructs with unprecedented precision. This technical capability has reoriented how teams approach hypothesis testing, moving away from one-size-fits-all models toward tailored constructs that match the mechanistic questions and endpoints under study. At the same time, phenotyping and in vivo imaging modalities have advanced to deliver richer, multimodal readouts that improve the interpretability of preclinical signals.

Parallel to these scientific shifts, organizational models for research delivery have evolved. Sponsors increasingly balance in-house capabilities with outsourced services, choosing contract research organizations for specialized assays while retaining core discovery activities internally. This hybrid approach affects procurement, timelines, and data ownership considerations, and it underscores the growing importance of vendor governance and quality assurance protocols. Ethical and welfare expectations have also heightened, prompting revised housing, enrichment, and experimental design practices that both improve animal welfare and reduce confounding variability.

Collectively, these shifts create a more capability-rich but also more complex operating environment. Organizations that codify decision criteria for model selection, integrate advanced phenotyping early in study design, and establish clear vendor performance metrics will gain a practical advantage in translating preclinical signals into robust proof-of-concept data.

Evaluating how the cumulative tariff actions enacted in 2025 compelled supply chain resilience, procurement redesign, and geographic reallocation of preclinical operations

Tariff policy changes and associated trade measures established for 2025 introduced new cost dynamics and operational considerations across global supply chains that support preclinical research. Procurement teams and facility managers now face a more complex calculus when sourcing animals, specialty diets, equipment, and imported reagents. Given the interdependence of breeding programs, medical supplies, and specialized consumables, even modest tariff increments can affect lead times and inventory strategies. Consequently, stakeholders have adopted more proactive supplier diversification, localized sourcing where feasible, and expanded safety stock strategies to mitigate disruption.

Beyond procurement, tariff-driven shifts influence strategic decisions about where to perform certain activities. Sponsors and service providers are re-evaluating the geographic allocation of breeding colonies, cryopreservation repositories, and specialized phenotyping centers to reduce exposure to cross-border cost volatility. Regulatory interactions also reflect this recalibration; agencies and institutional review boards are increasingly attentive to the provenance of animals and materials, prompting more detailed sourcing documentation and chain-of-custody processes.

Operational teams have responded by strengthening supplier relationships, negotiating longer-term contracts, and investing in supply chain visibility tools that provide early warning on cost and delivery risks. In sum, the cumulative impact of tariff actions in 2025 compelled the sector to adopt more resilient procurement strategies and to reexamine the geographic footprint of preclinical operations in order to maintain continuity of research and control costs.

Deep segmentation-driven understanding linking animal species, model constructs, research applications, end users, distribution channels, research types, and service modalities to operational decisions

Segment-level insight reveals the granular considerations that drive experimental design, vendor selection, and portfolio prioritization across the rat and mouse model landscape. Based on Animal, the market is studied across Mouse and Rat, and this fundamental dichotomy influences physiological relevance, study scope, and husbandry needs; mice often serve as the primary platform for genetic manipulations while rats are frequently preferred for studies requiring larger blood volumes or behavioral assays that benefit from greater cognitive complexity. Based on Model Type, the market is studied across Disease Specific, Knockout, Transgenic, and Xenograft constructs, with Disease Specific models further characterized across Cardiovascular Disorders, Infectious Disease Models, Metabolic Disorders, Neurological Disorders, and Oncology Models; the selection between knockout, transgenic, and disease-specific constructs is driven by the mechanistic question, required phenotype fidelity, and downstream translational considerations.

Based on Application, the market is studied across Cardiovascular, Immunology, Infectious Disease, Metabolic Disorder, Neurology, Oncology, and Orthopedic domains, and each application area imposes distinct endpoint requirements, assay complexity, and welfare considerations. Based on End User, the market is studied across Academic & Research Institutes, CROs, and Pharma & Biotech, and end-user priorities shape purchasing cycles, demand for bespoke services, and expectations for data packages and regulatory support. Based on Distribution Channel, the market is studied across Direct and Distributors, which affects lead times, pricing structures, and traceability. Based on Research Type, the market is studied across ADME, Behavioral, Efficacy, Safety Pharmacology, and Toxicology, and the chosen research type dictates study design complexity, required instrumentation, and regulatory documentation. Based on Service Type, the market is studied across Catalog and Custom options, with catalog services offering standardized, off-the-shelf models and custom services delivering bespoke genetic constructs and study formats tailored to unique scientific questions.

These segmentation dimensions intersect to create highly context-dependent decision pathways. For instance, an oncology xenograft study for a small-molecule efficacy readout will prioritize different vendors, housing conditions, and data packages than a neurological knockout model designed to elucidate disease mechanisms. Recognizing these interactions enables stakeholders to align procurement, ethical oversight, and data integration strategies with the nuanced demands of each experimental configuration.

Regional operational realities and regulatory nuances that determine model sourcing, study sequencing, and strategic placement of breeding and phenotyping capacity across global research hubs

Regional dynamics materially influence how organizations design studies, source resources, and plan regulatory strategies across the rat and mouse model landscape. In the Americas, research hubs combine a concentration of academic institutions, biotech startups, and integrated pharmaceutical R&D centers that demand rapid access to specialized models and high-throughput phenotyping; this environment fosters innovation in service delivery and a premium on speed and data completeness. Europe, Middle East & Africa presents a mosaic of regulatory frameworks and infrastructure maturity, where centers of excellence coexist with emerging markets; here, harmonization efforts and regional centers of breeding and phenotyping play an important role in enabling multicenter studies while ethical standards and welfare guidelines remain a focal point for operational planning. Asia-Pacific has rapidly expanded capacity in both commercial service provision and academic research, with significant investments in breeding infrastructure and specialized CRO capabilities; stakeholders in this region often emphasize cost-efficiency, scale, and the ability to execute high-volume study programs while increasingly meeting international standards for data quality and animal welfare.

Cross-regional collaboration and sample movement introduce logistical challenges that require clear chain-of-custody protocols and alignment on welfare and transport standards. Moreover, regional regulatory expectations and import/export controls shape how sponsors sequence studies across sites and choose where to domicile breeding colonies or long-term storage facilities. An informed regional strategy thus balances local capabilities with global coordination to optimize turnaround times, maintain compliance, and preserve the integrity of translational signals.

Competitive positioning insights illustrating how quality assurance, customization breadth, collaborative partnerships, and client service excellence drive market leadership

Leading companies that operate in the rat and mouse model ecosystem demonstrate a shared emphasis on quality assurance, customization capability, and integrated data services. Market-facing organizations that differentiate themselves invest in robust breeding programs, genetic validation workflows, and standardized phenotyping pipelines that reduce inter-study variability and improve reproducibility. In addition, service providers that offer modular packages-combining model generation, husbandry, in-life monitoring, and comprehensive data analytics-help sponsors shorten timelines and lower translational risk.

Partnerships and collaborations constitute another important axis of competitive positioning. Successful companies build deep scientific relationships with academia and industry, co-develop models for niche therapeutic areas, and participate in consortia that promote standardization. They also provide transparent quality metrics, traceability documentation, and regulatory support that align with sponsor expectations for preclinical dossiers. Companies that expand geographically while maintaining consistent husbandry and validation standards have demonstrated the ability to support multinational programs more reliably.

Finally, a focus on customer experience and technical support differentiates top-tier providers. Attention to study design consultation, responsive project management, and post-study data services creates enduring client relationships and positions these companies to capture a larger share of complex, high-value program work.

Practical and prioritized actions for leaders to strengthen model selection, supplier governance, early validation, data integration, and welfare practices to improve translational outcomes

Industry leaders should adopt a set of pragmatic actions to convert insight into operational advantage and enhance translational yield from rat and mouse studies. First, codify model-selection decision frameworks that tie biological hypothesis to model attributes, phenotyping requirements, and regulatory endpoints; such frameworks reduce subjective selection bias and clarify the trade-offs between transgenic constructs, knockout approaches, and disease-specific models. Next, invest in early-stage phenotyping and pilot studies to validate key endpoints before committing to large-scale efficacy programs; this staged approach reduces downstream failure risk and enables better resource allocation.

It is also critical to strengthen supplier governance and diversify sourcing strategies to mitigate exposure to regional disruptions and tariff-driven cost volatility. Establishing preferred-provider agreements that include performance metrics, data deliverables, and contingency clauses will improve reliability. Organizations should further embed data integration capabilities and digital phenotype repositories to amplify the value of in-life and terminal data, enabling meta-analyses and cross-study learning. Enhancing welfare and enrichment programs improves animal well-being and reduces experimental noise; aligning such practices with transparent reporting supports regulatory confidence and reproducibility.

Finally, cultivate strategic partnerships with providers that offer integrated, end-to-end services and prioritize readability of data packages. These partnerships should be evaluated not only on cost but on quality controls, validation documentation, and the ability to co-design studies that align with translational endpoints. Implementing these recommendations will improve decision velocity, reduce operational risk, and elevate the predictive value of preclinical work.

Transparent mixed-method research approach combining primary stakeholder interviews, technical literature alignment, vendor capability comparison, and supply chain scenario analysis

The findings summarized here rest on a mixed-method research approach that combined primary stakeholder engagement, rigorous literature synthesis, and comparative operational analysis. Primary research included structured interviews with institutional researchers, procurement leads, and service-provider operations managers to surface real-world constraints and priorities. The qualitative insights were triangulated with technical literature and regulatory guidance to ensure alignment with current best practices and evolving expectations for animal welfare, sourcing transparency, and study design.

Analysts also conducted a comparative review of vendor capabilities and service portfolios, assessing factors such as genetic validation processes, phenotyping depth, and data deliverable quality. The methodology prioritized reproducibility and traceability, placing particular emphasis on how suppliers document lineage, genotype confirmation, and study metadata. Supply chain resilience considerations were evaluated through scenario analysis focused on procurement lead times, import/export constraints, and supplier concentration risks.

Throughout the research process, efforts were made to remove promotional bias and to validate claims through cross-verification with multiple independent sources. The approach aimed to generate actionable insights while maintaining methodological transparency and reproducibility for readers seeking to evaluate or replicate the analysis.

Synthesis of strategic conclusions emphasizing how deliberate model selection, rigorous validation, integrated data strategies, and supply resilience improve translational success

In conclusion, rat and mouse models remain indispensable tools for preclinical discovery and development, yet their value depends on deliberate model selection, rigorous validation, and resilient operational practices. Advances in genetic engineering and phenotyping have expanded the range of experimental possibilities while raising the bar for quality assurance and reproducibility. Tariff-related supply chain pressures further incentivize proactive procurement strategies and geographic diversification of capabilities. Taken together, these forces demand that organizations align scientific choices with operational realities and embed stronger governance across sourcing, study design, and data management.

The optimal path forward emphasizes staged validation, integrated data strategies, and selective partnerships that provide both technical depth and logistical reliability. By doing so, sponsors and service providers can reduce translational risk, accelerate development decisions, and improve the scientific integrity of preclinical findings. The conclusions drawn here offer a strategic foundation for teams seeking to convert preclinical insight into clinically meaningful programs while managing cost, compliance, and operational complexity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rat & Mouse Model Market, by Species

  • 8.1. Rat Models
    • 8.1.1. Outbred Rat Models
    • 8.1.2. Inbred Rat Models
    • 8.1.3. Genetically Engineered Rat Models
    • 8.1.4. Immunodeficient Rat Models
  • 8.2. Mouse Models
    • 8.2.1. Outbred Mouse Models
    • 8.2.2. Inbred Mouse Models
    • 8.2.3. Genetically Engineered Mouse Models
      • 8.2.3.1. Knockout Mouse Models
      • 8.2.3.2. Transgenic Mouse Models
      • 8.2.3.3. Humanized Mouse Models
    • 8.2.4. Immunodeficient Mouse Models
      • 8.2.4.1. Nude Mouse Models
      • 8.2.4.2. SCID Mouse Models
      • 8.2.4.3. NOG/NSG Mouse Models

9. Rat & Mouse Model Market, by Model Type

  • 9.1. Inbred Models
  • 9.2. Outbred Models
  • 9.3. Genetically Engineered Models
    • 9.3.1. Knockout Models
      • 9.3.1.1. Constitutive Knockout Models
      • 9.3.1.2. Conditional Knockout Models
      • 9.3.1.3. Inducible Knockout Models
    • 9.3.2. Transgenic Models
    • 9.3.3. Humanized Models
    • 9.3.4. Knock-in Models
  • 9.4. Xenograft Models
    • 9.4.1. Cell Line-Derived Xenograft Models
    • 9.4.2. Patient-Derived Xenograft Models
  • 9.5. Syngeneic Models
  • 9.6. Chemically Induced Models
  • 9.7. Diet-Induced Models
  • 9.8. Surgically Induced Models
  • 9.9. Spontaneous Disease Models
  • 9.10. Reporter Models

10. Rat & Mouse Model Market, by Service Type

  • 10.1. Standard Model Supply
    • 10.1.1. Live Animals
    • 10.1.2. Cryopreserved Embryos & Sperm
  • 10.2. Custom Model Generation
    • 10.2.1. Gene Editing Design & Construction
    • 10.2.2. Embryology & Microinjection Services
    • 10.2.3. Validation & Quality Control
  • 10.3. Breeding & Colony Management
    • 10.3.1. Breeding Strategy Design
    • 10.3.2. Colony Expansion & Maintenance
    • 10.3.3. Health Monitoring
  • 10.4. Cryopreservation & Recovery
    • 10.4.1. Sperm Cryopreservation
    • 10.4.2. Embryo Cryopreservation
    • 10.4.3. Resuscitation Services
  • 10.5. Rederivation & Health Status Improvement
  • 10.6. Phenotyping & Behavior Testing
    • 10.6.1. Physiological Phenotyping
    • 10.6.2. Behavioral & Cognitive Testing
  • 10.7. In Vivo Study Services
    • 10.7.1. Efficacy Studies
    • 10.7.2. Disease Induction & Monitoring
    • 10.7.3. Surgical Modeling
  • 10.8. Consulting & Regulatory Support

11. Rat & Mouse Model Market, by Application

  • 11.1. Drug Discovery & Screening
    • 11.1.1. Target Identification & Validation
    • 11.1.2. High-Throughput Screening
    • 11.1.3. Lead Optimization
  • 11.2. Preclinical Efficacy Studies
    • 11.2.1. Dose-Response Studies
    • 11.2.2. Combination Therapy Studies
  • 11.3. Pharmacokinetics & Pharmacodynamics
    • 11.3.1. Absorption, Distribution, Metabolism & Excretion
    • 11.3.2. Exposure-Response Modeling
  • 11.4. Safety & Toxicology Testing
    • 11.4.1. Acute Toxicity
    • 11.4.2. Chronic Toxicity
    • 11.4.3. Carcinogenicity
    • 11.4.4. Reproductive & Developmental Toxicity
  • 11.5. Disease Mechanism & Pathophysiology Research
  • 11.6. Biomarker Discovery & Validation
  • 11.7. Translational & Biomimetic Studies
  • 11.8. Education & Training

12. Rat & Mouse Model Market, by End User

  • 12.1. Pharmaceutical Companies
    • 12.1.1. Top-Tier & Multinational Pharma
    • 12.1.2. Mid-Size & Specialty Pharma
  • 12.2. Biotechnology Companies
    • 12.2.1. Established Biotech Firms
    • 12.2.2. Emerging & Virtual Biotech
  • 12.3. Contract Research Organizations
    • 12.3.1. Global CROs
    • 12.3.2. Niche Preclinical CROs
  • 12.4. Academic & Research Institutes
    • 12.4.1. Universities
    • 12.4.2. Independent Research Institutes
  • 12.5. Government & Public Sector Laboratories
  • 12.6. Nonprofit & Foundations
  • 12.7. Industry Consortia & Partnerships

13. Rat & Mouse Model Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Rat & Mouse Model Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Rat & Mouse Model Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Rat & Mouse Model Market

17. China Rat & Mouse Model Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Biocytogen Pharmaceuticals Co., Ltd.
  • 18.6. Champions Oncology, Inc.
  • 18.7. Charles River Laboratories International, Inc.
  • 18.8. Crown Bioscience International, Inc.
  • 18.9. Cyagen Biosciences, Inc.
  • 18.10. Envigo RMS, LLC
  • 18.11. GemPharmatech Co., Ltd.
  • 18.12. genOway S.A.
  • 18.13. Harbour BioMed
  • 18.14. Hera BioLabs, Inc.
  • 18.15. inGenious Targeting Laboratory, Inc.
  • 18.16. Janvier Labs SA
  • 18.17. Oncodesign Precision Medicine
  • 18.18. Oriental BioService Co., Ltd.
  • 18.19. Ozgene Pty Ltd.
  • 18.20. PerkinElmer, Inc.
  • 18.21. Pharmatest Services Oy
  • 18.22. PolyGene AG
  • 18.23. Taconic Biosciences, Inc.
  • 18.24. The Jackson Laboratory
  • 18.25. TransCure bioServices
  • 18.26. TransTech Pharma, Inc.
  • 18.27. TransViragen, Inc.
  • 18.28. Vivo Bio Tech Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RAT & MOUSE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RAT & MOUSE MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RAT & MOUSE MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RAT & MOUSE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RAT & MOUSE MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RAT & MOUSE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY OUTBRED RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY OUTBRED RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY OUTBRED RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INBRED RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INBRED RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INBRED RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY OUTBRED MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY OUTBRED MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY OUTBRED MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INBRED MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INBRED MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INBRED MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TRANSGENIC MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TRANSGENIC MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TRANSGENIC MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HUMANIZED MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HUMANIZED MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HUMANIZED MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT MOUSE MODELS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY NUDE MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY NUDE MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY NUDE MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SCID MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SCID MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SCID MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY NOG/NSG MOUSE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY NOG/NSG MOUSE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY NOG/NSG MOUSE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INBRED MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INBRED MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INBRED MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY OUTBRED MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY OUTBRED MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY OUTBRED MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MODELS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONSTITUTIVE KNOCKOUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONSTITUTIVE KNOCKOUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONSTITUTIVE KNOCKOUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONDITIONAL KNOCKOUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONDITIONAL KNOCKOUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONDITIONAL KNOCKOUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INDUCIBLE KNOCKOUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INDUCIBLE KNOCKOUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY INDUCIBLE KNOCKOUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HUMANIZED MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HUMANIZED MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HUMANIZED MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY XENOGRAFT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY XENOGRAFT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY XENOGRAFT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY XENOGRAFT MODELS, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CELL LINE-DERIVED XENOGRAFT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CELL LINE-DERIVED XENOGRAFT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CELL LINE-DERIVED XENOGRAFT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SYNGENEIC MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SYNGENEIC MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SYNGENEIC MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CHEMICALLY INDUCED MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CHEMICALLY INDUCED MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CHEMICALLY INDUCED MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DIET-INDUCED MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DIET-INDUCED MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DIET-INDUCED MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SURGICALLY INDUCED MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SURGICALLY INDUCED MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SURGICALLY INDUCED MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPONTANEOUS DISEASE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPONTANEOUS DISEASE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPONTANEOUS DISEASE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REPORTER MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REPORTER MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REPORTER MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY STANDARD MODEL SUPPLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY STANDARD MODEL SUPPLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY STANDARD MODEL SUPPLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY STANDARD MODEL SUPPLY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY LIVE ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY LIVE ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY LIVE ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVED EMBRYOS & SPERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVED EMBRYOS & SPERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVED EMBRYOS & SPERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CUSTOM MODEL GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CUSTOM MODEL GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CUSTOM MODEL GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CUSTOM MODEL GENERATION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENE EDITING DESIGN & CONSTRUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENE EDITING DESIGN & CONSTRUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GENE EDITING DESIGN & CONSTRUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EMBRYOLOGY & MICROINJECTION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EMBRYOLOGY & MICROINJECTION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EMBRYOLOGY & MICROINJECTION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY VALIDATION & QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY VALIDATION & QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY VALIDATION & QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BREEDING & COLONY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BREEDING & COLONY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BREEDING & COLONY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BREEDING & COLONY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BREEDING STRATEGY DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BREEDING STRATEGY DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BREEDING STRATEGY DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COLONY EXPANSION & MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COLONY EXPANSION & MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COLONY EXPANSION & MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HEALTH MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HEALTH MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HEALTH MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVATION & RECOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVATION & RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVATION & RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVATION & RECOVERY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPERM CRYOPRESERVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPERM CRYOPRESERVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPERM CRYOPRESERVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY RESUSCITATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY RESUSCITATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY RESUSCITATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REDERIVATION & HEALTH STATUS IMPROVEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REDERIVATION & HEALTH STATUS IMPROVEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REDERIVATION & HEALTH STATUS IMPROVEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHENOTYPING & BEHAVIOR TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHENOTYPING & BEHAVIOR TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHENOTYPING & BEHAVIOR TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHENOTYPING & BEHAVIOR TESTING, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHYSIOLOGICAL PHENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHYSIOLOGICAL PHENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHYSIOLOGICAL PHENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BEHAVIORAL & COGNITIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BEHAVIORAL & COGNITIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BEHAVIORAL & COGNITIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IN VIVO STUDY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IN VIVO STUDY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IN VIVO STUDY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY IN VIVO STUDY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EFFICACY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EFFICACY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EFFICACY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DISEASE INDUCTION & MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DISEASE INDUCTION & MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DISEASE INDUCTION & MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SURGICAL MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SURGICAL MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SURGICAL MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONSULTING & REGULATORY SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONSULTING & REGULATORY SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONSULTING & REGULATORY SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DRUG DISCOVERY & SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DRUG DISCOVERY & SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DRUG DISCOVERY & SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DRUG DISCOVERY & SCREENING, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HIGH-THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HIGH-THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PRECLINICAL EFFICACY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PRECLINICAL EFFICACY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PRECLINICAL EFFICACY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PRECLINICAL EFFICACY STUDIES, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DOSE-RESPONSE STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DOSE-RESPONSE STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DOSE-RESPONSE STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COMBINATION THERAPY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COMBINATION THERAPY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COMBINATION THERAPY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHARMACOKINETICS & PHARMACODYNAMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHARMACOKINETICS & PHARMACODYNAMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHARMACOKINETICS & PHARMACODYNAMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHARMACOKINETICS & PHARMACODYNAMICS, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ABSORPTION, DISTRIBUTION, METABOLISM & EXCRETION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ABSORPTION, DISTRIBUTION, METABOLISM & EXCRETION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ABSORPTION, DISTRIBUTION, METABOLISM & EXCRETION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EXPOSURE-RESPONSE MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EXPOSURE-RESPONSE MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EXPOSURE-RESPONSE MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SAFETY & TOXICOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SAFETY & TOXICOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SAFETY & TOXICOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SAFETY & TOXICOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ACUTE TOXICITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ACUTE TOXICITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ACUTE TOXICITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CHRONIC TOXICITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CHRONIC TOXICITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CHRONIC TOXICITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CARCINOGENICITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CARCINOGENICITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CARCINOGENICITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REPRODUCTIVE & DEVELOPMENTAL TOXICITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REPRODUCTIVE & DEVELOPMENTAL TOXICITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REPRODUCTIVE & DEVELOPMENTAL TOXICITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DISEASE MECHANISM & PATHOPHYSIOLOGY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DISEASE MECHANISM & PATHOPHYSIOLOGY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY DISEASE MECHANISM & PATHOPHYSIOLOGY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BIOMARKER DISCOVERY & VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BIOMARKER DISCOVERY & VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BIOMARKER DISCOVERY & VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TRANSLATIONAL & BIOMIMETIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TRANSLATIONAL & BIOMIMETIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TRANSLATIONAL & BIOMIMETIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EDUCATION & TRAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EDUCATION & TRAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EDUCATION & TRAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TOP-TIER & MULTINATIONAL PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TOP-TIER & MULTINATIONAL PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY TOP-TIER & MULTINATIONAL PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MID-SIZE & SPECIALTY PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MID-SIZE & SPECIALTY PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MID-SIZE & SPECIALTY PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ESTABLISHED BIOTECH FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ESTABLISHED BIOTECH FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ESTABLISHED BIOTECH FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EMERGING & VIRTUAL BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EMERGING & VIRTUAL BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY EMERGING & VIRTUAL BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GLOBAL CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 283. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GLOBAL CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GLOBAL CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY NICHE PRECLINICAL CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 286. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY NICHE PRECLINICAL CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY NICHE PRECLINICAL CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 289. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 292. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 293. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD